Meta AnalysisID 7011
头皮和非头皮脂溢性皮炎的治疗干预：系统评价与网状Meta分析
CRD42023440667
To summarize and synthesize all available evidence from randomized controlled trials that compare the efficacy, tolerability, and safety profile of treatment interventions for adolescents and adults with scalp and non-sc
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7011
- Evidence Id
- 15569
- Core Evidence Id
- 15569
- Source Meta Analysis Id
- 6997
- Herb2 Meta Analysis Id
- HBMA006997
- Crd Id
- CRD42023440667
- Title
- Treatment Interventions for Scalp and Non-Scalp Seborrheic Dermatitis: A Systematic Review and Network Meta-Analysis
- Review Question
- To summarize and synthesize all available evidence from randomized controlled trials that compare the efficacy, tolerability, and safety profile of treatment interventions for adolescents and adults with scalp and non-scalp seborrheic dermatitis.
- Study Type Included
- Published randomized controlled trials (RCTs) with at least 20 patients will be included in any setting and context. Preprints and letters will also be included if they describe original research that provided data on treatment interventions among participants with scalp or non-scalp seborrheic dermatitis. In vivo/in vitro, animal studies, case reports, non-randomized studies, observational studies, and systematic reviews will be excluded.
- Condition Being Studied
- Adolescents and adults with scalp or non-scalp (face/retroauricular area, upper chest, and body folds) seborrheic dermatitis.
- Participant
- Adult and adolescent participants aged 12 years or more, regardless of comorbid conditions. Trials including participants with infantile seborrheic dermatitis will be excluded.
- Animal
- Human Disease Modelled
- Intervention
- Treatment interventions in any route of administration will be considered: e.g., emollients (white petrolatum ointment), keratolytics (salicylic acid, coal tar), antifungals (ciclopirox, ketoconazole, itraconazole, terbinafine, fluconazole, sertaconazole, clotrimazole, pramiconazole, bifonazole), nonsteroidal antiinflammatory agent with antifungal properties (piroctone lomine, alglycera, bisabolol, glycyrrhetic acid, lactoferrin), corticosteroids (hydrocortisone, fluocinolone acetonide, clobetasol propionate, alclometasone, methylprednisolone, mometasone furoate, betamethasone), calcinurin inhibitors (pimecrolimus, tacrolimus), phosphodiesterase 4 inhibitors (crisaborole, apremilast, roflumilast), vitamin D analogs (calcipotriol, tacalcitol), other agents (selenium sulphide, sulfur/sulfacetamide, zinc pyrithione, metronidazole, lithium, nicotinamide, hyaluronic acid, desonide, Promiseb®), natural products or complementary and alternative medicine (tanshinone, aloe vera, tea tree oil, Quassia amara), and non-pharmacologic interventions (phototherapy).
- Comparator Control
- Placebo, active comparator, different dosage regimen, or usual care.
- Main Outcome
- (i) Investigator global assessment—treatment response: changes in severity score or clinical symptom score (ii) Investigator global assessment—Complete clearance (complete disappearance of disease or clinical cure) or clinical improvement (iii) Unacceptability of treatment: study discontinuation because of any cause (iv) Tolerability of treatment: study discontinuation due to adverse event (v) Incidence of treatment-emergent adverse events: patient with at least one reported adverse event Measures of effect Mean differences/mean change from baseline (standardized mean differences [SMDs]), the incidence of the outcome of interests, hazard ratios (HRs), risk ratios (RRs), odds ratios (ORs): All-time points as defined by the specific studies.
- Outcome Measure
- Additional Outcome
- (i) Change in disease activity (e.g., erythema, scaling, pruritus, infiltration) (ii) Mycological cure (iii) Recurrent rate (iv) Patient-reported health-related quality of life (v) Other patient-reported outcomes (e.g., treatment satisfaction) (vi) Psychosocial aspects: depressive symptoms, anxiety, distress, and well-being (vii) Incidence of any serious adverse event: patients with at least one reported serious adverse event (viii) Healthcare utilization and costs Measures of effect Mean differences/mean change from baseline (standardized mean differences [SMDs]), the incidence of the outcome of interests, hazard ratios (HRs), risk ratios (RRs), odds ratios (ORs): All-time points as defined by the specific studies.
- Study Method
- Living systematic review, Meta-analysis, Network meta-analysis, Systematic review
- Keyword
- Adolescent; Adult; Dermatitis, Seborrheic; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Scalp
- Contact
- Surapon Nochaiwong [email protected]
- Organisational Affiliation
- Chiang Mai University
- Funding Source
- Pharmacoepidemiology and Statistics Research Center (PESRC), Chiang Mai, Thailand
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Thailand
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-06-28
- Registration Date
- 2023-07-10
- Anticipated Start Date
- 2023-06-30
- Anticipated Completion Date
- 2025-06-29
- Title Cn
- 头皮和非头皮脂溢性皮炎的治疗干预：系统评价与网状Meta分析
- Title En
- Treatment Interventions for Scalp and Non-Scalp Seborrheic Dermatitis: A Systematic Review and Network Meta-Analysis
- Bilingual Status
- complete